Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | PPARG | P37231 | 2/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242795 | 0.91 | EGFR (0.68) | KDM4EALDH1A1EGFRSRCPPARG | |
| SCHEMBL22118464 | 0.90 | EGFR (0.62) | KDM4EALDH1A1EGFRSRCPPARG | |
| SCHEMBL31006372 | 0.90 | EGFR (0.62) | KDM4EALDH1A1EGFRSRCPPARG | |
| Phenylhydrazine SCHEMBL8218750 | 0.88 | KDM4E (0.54) | KDM4EALDH1A1EGFRSRCPPARG | |
| SCHEMBL22118419 | 0.86 | HTR2A (0.60) | KDM4EALDH1A1EGFRSRCPPARG | |
| SCHEMBL31006391 | 0.86 | HTR2A (0.60) | KDM4EALDH1A1EGFRSRCPPARG | |
| SCHEMBL22769576 | 0.85 | CNR1 (0.55) | EGFRSRCCNR1HTR2AHTR2C | |
| SCHEMBL5211637 | 0.85 | ALDH1A1 (0.68) | KDM4EALDH1A1EGFRPPARGCNR1 | |
| SCHEMBL6625732 | 0.84 | GPR17 (0.66) | KDM4EALDH1A1EGFRSRCPPARG | |
| SCHEMBL22160189 | 0.84 | GPR17 (0.57) | KDM4EALDH1A1EGFRSRCPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
| CN-1613012-A | Soluble cd40l (cd154) as a prognostic marker of atherosclerotic diseases | BRIGHAM & WOMENS HOSPITAL (US) | 2005-05-04 | — | — | CN | disclosed |
| EP-0858996-B1 | NERVE CELL PROTECTIVE AGENTS | MOCHIDA PHARM CO LTD (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-0858996-A1 | NERVE CELL PROTECTIVE AGENTS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-4522808-A | Anti-sunburn compositions containing 2-phenyl-indole derivatives | SOCIETE ANONYME DITE: L'OREAL (FR) | 1985-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | KDM4E 4311/4885ALDH1A1 3319/4885EGFR 935/4885 |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | KDM4E 4249/4885ALDH1A1 3269/4885EGFR 1584/4885 |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, SAAL1, LOXL1 | KDM4E 4380/4885ALDH1A1 1956/4885EGFR 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.